Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Crizotinib
Drug ID BADD_D00535
Description Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Indications and Usage Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Marketing Status approved
ATC Code L01ED01
DrugBank ID DB08865
KEGG ID D09731
MeSH ID D000077547
PubChem ID 11626560
TTD Drug ID D03ZBT
NDC Product Code 68724-1020; 53869-2231; 53869-2230; 0069-8140; 0069-8141
UNII 53AH36668S
Synonyms Crizotinib | PF-02341066 | PF-2341066 | PF 2341066 | PF2341066 | PF 02341066 | PF02341066 | Xalkori
Chemical Information
Molecular Formula C21H22Cl2FN5O
CAS Registry Number 877399-52-5
SMILES CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrooesophageal reflux disease07.02.02.0030.003929%
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal perforation07.04.04.001--Not Available
Generalised oedema14.05.06.007; 08.01.07.0040.000504%
Guillain-Barre syndrome17.09.01.001; 11.07.01.001; 10.04.10.0050.000168%
Haemangioma24.03.06.004; 16.02.01.0020.000246%Not Available
Haemoglobin decreased13.01.05.003--Not Available
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.0040.001220%Not Available
Halo vision06.02.06.0030.000437%Not Available
Headache17.14.01.001--
Hemiparesis17.01.04.0010.000224%
Hepatic cirrhosis09.01.04.0010.000224%Not Available
Hepatic cyst16.06.02.001; 09.01.08.0080.000112%Not Available
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.000280%Not Available
Hepatic failure09.01.03.0020.000783%
Hepatic function abnormal09.01.02.0010.003112%Not Available
Hepatic necrosis09.01.07.0020.000112%
Hepatitis09.01.07.0040.001623%Not Available
Hepatitis acute09.01.07.0050.000504%Not Available
Hepatitis fulminant11.07.01.003; 09.01.07.0070.000336%Not Available
Hepatitis toxic12.03.01.016; 09.01.07.0170.000168%Not Available
Hepatocellular injury09.01.07.0080.000951%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.001690%Not Available
Hernia08.01.04.0010.000302%Not Available
Hydronephrosis20.01.05.0010.000112%Not Available
Hyperaesthesia17.02.06.004; 23.03.03.0800.000381%Not Available
Hyperbilirubinaemia09.01.01.003; 14.11.01.010; 01.06.04.0030.000280%Not Available
Hyperkalaemia14.05.03.0010.000974%
Hypoaesthesia17.02.06.023; 23.03.03.0810.004399%Not Available
Hypoalbuminaemia14.10.01.002; 09.01.02.0030.000862%
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene